Literature DB >> 28147705

"It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa.

Karen B Jacobson1, Linda Niccolai2, Nonhle Mtungwa3, Anthony P Moll4, Sheela V Shenoi5.   

Abstract

Despite the recent rollout of Isoniazid Preventive Therapy (IPT) to prevent TB in people living with HIV in South Africa, adherence and completion rates are low. To explore barriers to IPT completion in rural KwaZulu-Natal, South Africa, we conducted individual semi-structured interviews among 30 HIV patients who had completed or defaulted IPT. Interview transcripts were analyzed according to the framework method of qualitative analysis. Facilitators of IPT completion included knowledge of TB and IPT, accepting one's HIV diagnosis, viewing IPT as similar to antiretroviral therapy, having social support in the community and the clinic, trust in the healthcare system, and desire for health preservation. Barriers included misunderstanding of IPT's preventive role in the absence of symptoms, inefficient health service delivery, ineffective communication with healthcare workers, financial burden of transport to clinic and lost wages, and competing priorities. HIV-related stigma was not identified as a significant barrier to IPT completion, and participants felt confident in their ability to manage stigma, for example by pretending their medications were for unrelated conditions. Completers were more comfortable communicating with health care workers than were defaulters. Efforts to facilitate successful IPT completion must include appropriate counseling and education for individual patients and addressing inefficiencies within the health care system in order to minimize patients' financial and logistical burden. These patient-level and structural changes are necessary for IPT to successfully reduce TB incidence in this resource-limited setting.

Entities:  

Keywords:  HIV/AIDS; Isoniazid preventive therapy; adherence; qualitative methods; tuberculosis

Mesh:

Substances:

Year:  2017        PMID: 28147705      PMCID: PMC5545149          DOI: 10.1080/09540121.2017.1283390

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  18 in total

Review 1.  Qualitative research in health care. Analysing qualitative data.

Authors:  C Pope; S Ziebland; N Mays
Journal:  BMJ       Date:  2000-01-08

2.  Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study.

Authors:  Rebecca Lester; Robin Hamilton; Salome Charalambous; Thobeka Dwadwa; Clare Chandler; Gavin J Churchyard; Alison D Grant
Journal:  AIDS       Date:  2010-11       Impact factor: 4.177

3.  Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings?

Authors:  K A Rowe; B Makhubele; J R Hargreaves; J D Porter; H P Hausler; P M Pronyk
Journal:  Int J Tuberc Lung Dis       Date:  2005-03       Impact factor: 2.373

4.  Adherence to tuberculosis preventive therapy among HIV-infected persons in Chiang Rai, Thailand.

Authors:  J Ngamvithayapong; W Uthaivoravit; H Yanai; P Akarasewi; P Sawanpanyalert
Journal:  AIDS       Date:  1997-01       Impact factor: 4.177

5.  Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa.

Authors:  Amrita Daftary; Nesri Padayatchi; Max O'Donnell
Journal:  Glob Public Health       Date:  2014-07-18

6.  Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting.

Authors:  Clare L van Halsema; Katherine L Fielding; Violet N Chihota; Elizabeth C Russell; James J C Lewis; Gavin J Churchyard; Alison D Grant
Journal:  AIDS       Date:  2010-04-24       Impact factor: 4.177

7.  Adherence to isoniazid preventive therapy in Indonesian children: A quantitative and qualitative investigation.

Authors:  Merrin E Rutherford; Rovina Ruslami; Winni Maharani; Indria Yulita; Sarah Lovell; Reinout Van Crevel; Bachti Alisjahbana; Philip C Hill
Journal:  BMC Res Notes       Date:  2012-01-06

8.  Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa.

Authors:  Tom A Szakacs; Douglas Wilson; D William Cameron; Michael Clark; Paul Kocheleff; F James Muller; Anne E McCarthy
Journal:  BMC Infect Dis       Date:  2006-06-13       Impact factor: 3.090

Review 9.  Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: a systematic review of qualitative data.

Authors:  Titilola Makanjuola; Henock B Taddese; Andrew Booth
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

10.  A recent HIV diagnosis is associated with non-completion of Isoniazid Preventive Therapy in an HIV-infected cohort in Cape Town.

Authors:  Tolu Oni; Relebohile Tsekela; Bekekile Kwaza; Lulama Manjezi; Nonzwakazi Bangani; Katalin A Wilkinson; David Coetzee; Robert J Wilkinson
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more
  19 in total

1.  Predictors of isoniazid preventive therapy completion among HIV-infected patients receiving differentiated and non-differentiated HIV care in rural Uganda.

Authors:  Khai Hoan Tram; Florence Mwangwa; Gabriel Chamie; Mucunguzi Atukunda; Asiphas Owaraganise; James Ayieko; Vivek Jain; Tamara D Clark; Dalsone Kwarisiima; Maya L Petersen; Moses R Kamya; Edwin D Charlebois; Diane V Havlir; Carina Marquez
Journal:  AIDS Care       Date:  2019-06-10

2.  Priorities among HIV-positive individuals for tuberculosis preventive therapies.

Authors:  H-Y Kim; C F Hanrahan; D W Dowdy; N A Martinson; J E Golub; J F P Bridges
Journal:  Int J Tuberc Lung Dis       Date:  2020-04-01       Impact factor: 2.373

3.  Choice architecture-based prescribing tool for TB preventive therapy: a pilot study in South Africa.

Authors:  G Caturegli; J Materi; A Lombardo; M Milovanovic; N Yende; E Variava; J E Golub; N A Martinson; C J Hoffmann
Journal:  Public Health Action       Date:  2020-09-21

4.  Promoting Tuberculosis Preventive Therapy for People Living with HIV in South Africa: Interventions Hindered by Complicated Clinical Guidelines and Imbalanced Patient-Provider Dynamics.

Authors:  Brooke A Jarrett; Daniel M Woznica; Carla Tilchin; Nthabiseng Mpungose; Katlego Motlhaoleng; Jonathan E Golub; Neil A Martinson; Colleen F Hanrahan
Journal:  AIDS Behav       Date:  2020-04

5.  Isoniazid Preventive Therapy Completion in the Era of Differentiated HIV Care.

Authors:  Khai Hoan Tram; Florence Mwangwa; Mucunguzi Atukunda; Asiphas Owaraganise; James Ayieko; Albert Plenty; Dalsone Kwariisima; Tamara D Clark; Maya L Petersen; Edwin D Charlebois; Moses R Kamya; Gabriel Chamie; Diane V Havlir; Carina Marquez
Journal:  J Acquir Immune Defic Syndr       Date:  2017-12-15       Impact factor: 3.731

6.  When prevention is dangerous: perceptions of isoniazid preventive therapy in KwaZulu-Natal, South Africa.

Authors:  J Boffa; M Mayan; S Ndlovu; D Fisher; S Staples; R Sauve; T Williamson
Journal:  Public Health Action       Date:  2019-03-21

7.  Structural barriers to implementing recommended tuberculosis preventive treatment in primary care clinics in rural South Africa.

Authors:  Divya K Chandra; Anthony P Moll; Frederick L Altice; Elizabeth Didomizio; Laurie Andrews; Sheela V Shenoi
Journal:  Glob Public Health       Date:  2021-03-02

8.  "We've Got Our Own Beliefs, Attitudes, Myths": A Mixed Methods Assessment of Rural South African Health Care Workers' Knowledge of and Attitudes Towards PrEP Implementation.

Authors:  Emmanuella Ngozi Asabor; Elle Lett; Anthony Moll; Sheela V Shenoi
Journal:  AIDS Behav       Date:  2021-03-24

9.  Integrated and patient-selected care facilitates completion of isoniazid preventive therapy in Eswatini.

Authors:  L V Adams; T S B Maseko; E A Talbot; S W Grande; M M Mkhontfo; Z Z Simelane; A A Achilla; S M Haumba
Journal:  Public Health Action       Date:  2019-12-21

10.  Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda-patient and health worker perspectives.

Authors:  Fred C Semitala; Allan Musinguzi; Jackie Ssemata; Fred Welishe; Juliet Nabunje; Jillian L Kadota; Christopher A Berger; Achilles Katamba; Noah Kiwanuka; Moses R Kamya; David Dowdy; Adithya Cattamanchi; Anne R Katahoire
Journal:  Implement Sci Commun       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.